drugset / Trial / NCT02691949

Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome

NCT02691949

Phase 2 Unknown 54 enrolled Kaohsiung Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

Past literature showed encouraging effects of mycophenolate on dryness symptoms and quality of life in patients with Sjogren's syndrome. Mycophenolate also has excellent immunomodulation effects in lupus nephritis. Currently Mycophenolate is only used in lupus nephritis and organ transplant. It is unknown whether low dosage of mycophenolate mofetil could be used to improve ocular dryness and oral dryness in patients with Sjogren's syndrome.

Timeline

Start
2016-02
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule 250 mg
Subject Mycophenolate Mofetil Small molecule 500 mg

Indications